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higher re-intervention rates with PTCA (2).  During
PTCA, the balloon is inflated at the site of
atherosclerotic narrowing, dilating the vessel lumen,
and causing compression of the plaque and stretching of
the vessel wall. Thus, the result is fracturing and
fissuring of the atheroma due to its inelastic
components and an extension into the vessel wall,
causing either superficial or deep arterial injury (Figure
1) (3).  
The response of vascular tissue to the injury caused
by balloon angioplasty accounted for its two major
limitations, which were acute vessel closure and
restenosis (renarrowing of the vessel). The incidence of
acute vessel closure was 3-5%, and would occur within
the first 24 hours of the procedure due to vessel
dissection or acute thrombus formation (3).
Restenosis can be defined as a reduction in the
luminal diameter of more than 50%. It had a high
incidence rate of 25-50% in patients having undergone
balloon angioplasty, with the vast majority of patients
requiring revascularisation within 6 months (3). This
occurred because of elastic recoil and intimal
hyperplasia as a response to vascular injury. 
Coronary artery stenting was then introduced with the
hope that the limitations of balloon angioplasty could be
overcome (4). This involved placing a stent, a metal
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BACKGROUND
For several decades, coronary artery bypass graft
(CABG) and percutaneous transluminal coronary
angioplasty (PTCA) have been the main procedures
used to treat coronary artery disease. CABG is a
surgical procedure whereby an obstruction in the
coronary arteries caused by an atherosclerotic plaque
can be treated using saphenous vein grafts or arterial
grafts such as internal mammary arteries to bypass the
obstruction (1). 
PTCA was introduced over 20 years ago as an
alternative coronary intervention to the more invasive
CABG. The procedure involves making small incisions
in the vessels of the groin or arm under local anaesthetic
where a catheter can be fed through to the obstructed
coronary vessel. A balloon attached to the end of the
catheter is used to unblock the vessel and consequently
restore the blood flow (1).
However, a number of studies in the early 1990s that
compared the outcomes of CABG with PTCA revealed
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ABSTRACT: Over the last three decades, percutaneous coronary intervention (PCI)
technology has revolutionized the field of cardiology. PCI began in the form of balloon
angioplasty, and was followed by coronary stenting. In-Stent restenosis is the main limitation
of coronary stenting, and has been delayed to some extent by the development of drug eluting
stents. Coronary angioplasty with stenting is currently the most popular non-medical
treatment of coronary artery disease therefore solving the problem of in-stent restenosis
could change the future role of other types of coronary intervention. This review examines
the types of percutaneous coronary interventions, the mechanisms leading up to in-stent
restenosis, and how previous and current treatments of in-stent restenosis influence the
vascular response to injury.  
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meshwork device, into the vascular lumen to keep the
vessel open and prevent acute vessel closure and
restenosis (5). Coronary stenting was shown to
significantly improve the outcome, including a 10%
reduction in restenosis rates compared to angioplasty
alone (6).  
This paper reviews the definition, pathophysiology,
and treatment of in-stent restenosis, as well as its
implications in the development of new stent designs.
PROCEDURES FOR BALLOON ANGIOPLASTY
AND STENTING
Under local anaesthetic, a guide catheter is introduced
into the femoral artery in the groin or the brachial artery
in the arm. The catheter reaches the aorta through the
artery, and is lodged within the aorta at the origin of the
coronary artery. To identify the areas of narrowing, a
radio-opaque contrast is injected into the coronary
artery and x-rays are used to produce a continuous
image (3).
A guide wire that runs along the middle of the guiding
catheter is passed down the coronary artery and through
the obstruction. A balloon-tipped catheter is then passed
over the guide wire placed at the stenosis ,and the
balloon is inflated. The coronary artery lumen is
widened, and the guide catheter, guide wire, and balloon
are withdrawn (3).
With coronary stenting, the stenosis may be stented
directly or dilated with a balloon before stenting (3).
With direct stenting, the stent (a tubular wire mesh) is
stretched into a constrained state with a special delivery
catheter and then gradually released at the site of the
stenosis. The radial forces of the stent on the vascular
wall lead to dilation of the vessel. 
With a balloon-expandable stent, the balloon is
inflated to expand the stent so that it holds the narrowed
vessel open. Finally, the balloon is deflated and
withdrawn (5).
DEFINITION OF IN-STENT RESTENOSIS
In-stent restenosis is defined as a decrease in the
luminal diameter by greater than 50% in the stented area
of the vessel, similar to post-angioplasty restenosis
(PARS). This is known as angiographic restenosis. As
with post-angioplasty restenosis, in-stent restenosis also
occurs within 6 months of stenting (6). 
Clinically, in-stent restenosis can present as recurrent
angina or myocardial ischaemia although angiographic
restenosis does not always lead to clinical symptoms
such as angina. In-stent restenosis can also be defined
by the relative length of the restenotic lesion: if the
lesion measures less than 10 mm, it is known as focal,
whereas if it measures more than 10 mm, it is known as
diffuse (6).
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PATHOPHYSIOLOGY OF RESTENOSIS
Restenosis occurs as a result of the response of the
vascular tissue to the injury caused by coronary
angioplasty (7). In the case of in-stent restenosis, it is
the result of vascular injury that occurs after stenting.
The injury caused by insertion of a stent is different
from the injury caused by angioplasty alone. This
results in differences in the pathophysiological
mechanisms that lead to restenosis in response to injury. 
The struts of the stent cause deep, focal injury to the
vascular tissue whereas the balloon inflation is less
controlled in stretching and fracturing the vessel wall.
Also, in stenting, the extensive, early thrombus can act
as a scaffold whereby cell proliferation and neointimal
hyperplasia can occur. Additionally, inserting a stent
causes permanent strain on the vessel wall as opposed
to the transient strain applied by the balloon. Finally,
with stenting, a foreign material remains in the vessel
unlike the withdrawal of the balloon in coronary
angioplasty (8). 
The response to injury hypothesis used to describe the
mechanisms that lead to atherosclerosis plays an
important role in restenosis. In this hypothesis, repeated
vascular injury causes endothelial denudation and
subsequently results in platelet adhesion, thrombus
formation and monocyte infiltration (7).
The leukocytes and platelets release cytokines,
vasoactive agents, and growth factors, which promote
an inflammatory response (9). Platelet-derived growth
factor can lead to smooth muscle cell proliferation and
migration into the intima to form the neointima (10). 
Three mechanisms that lead to the development of
restenosis are elastic recoil, neointimal proliferation,
and negative remodelling (11). Inflammation plays an
important role in linking the early vascular injury of
deendothelialization and thrombus deposition, to the
more chronic response of healing whereby cell
proliferation, cell migration, and extracellular matrix
synthesis leads to neointimal growth and a reduction in
lumen size (10).
Elastic Recoil
The intimal, medial, and adventitial layers of the
coronary arteries are separated by elastin fibres, namely
the internal and external elastic lamina. Elastic recoil is
a passive process that occurs in seconds to minutes as a
result of the elastic laminae applying opposing force to
the overstretch caused by balloon inflation. This
reduces the lumen by up to 40% (12, 13).   
In studies comparing balloon-injured and stented
arteries, the rigid scaffolding of the stent prevented
elastic recoil and subsequently stented arteries were
found to have a much larger initial gain in lumen size
(14, 15). 
Inflammatory Changes
Inflammatory response within the vessel wall
following PCI can be divided into three stages: early
thrombotic phase (hours to days), intermediate
recruitment phase (3-10 days), and the late neointimal
proliferation phase (weeks to months) (11).
Early Thrombotic Phase
Vascular injury caused by angioplasty and stenting
leads to endothelial denudation. Consequently,
exposure of the subintima of the vessel wall activates
platelet aggregation, which is followed by fibrin
deposition and formation of a thrombus (11, 13). With
stents, the injury is deeper and more focal, and thick
platelet rich mural thrombi form on the stent struts (8).
Intermediate Recruitment Phase
In this phase, there is recruitment of leukocytes aided
by adhesion molecules and chemoattractant agents (6).
Firm adhesion and transplatelet migration of the
leukocytes are aided by the integrin class of adhesion
molecules (16). For example, integrin molecule
MAC-1 (CD11b/CD18) promotes the adhesion of
polymorphonuclear leukocytes and monocytes to the
endothelial cells (10). MAC-1 expression is increased
following stenting (17).   
Chemokines are chemoattractant cytokines, which
lead to further leukocyte recruitment and infiltration.
The monocyte chemoattractant protein (MCP-1) is an
example of a chemokine secreted by activated platelets
(18). MCP-1 expression has been found to be elevated
in endothelial cells and vascular smooth muscle cells
following stenting (19) and levels of MCP-1 have been
shown to be persistently elevated in patients with
restenosis (20). 
Activated platelets release factors that activate
endothelial proliferation and smooth muscle migration
from the media to the intima (11). There is also
exposure of the arterial wall to circulating angiotensin II
and plasmin (13). Medial smooth muscle cells undergo
phenotypic modification from contractile to 'synthetic',
which leads to their migration to the intima and
subsequent proliferation there (6). 
Late Neointimal Proliferation Phase
Formation of new extracellular matrix in the intimal
tissue is coupled with synthesis of collagen to form the
neointima (6).
Over time, the thrombus is replaced by the neointima
and this increases up to 3 months after the procedure
(11). However, over subsequent months the neointimal
hyperplasia becomes composed of more extracellular
matrix and less cellular components (6).108 McGill Journal of Medicine 2007
Negative Remodelling
Vascular remodelling consist of the compensatory
changes that occur to the arterial size due to expansion
of the media and external elastic membrane. “Positive
remodelling” describes expansion in the external elastic
membrane area, and “negative remodelling” describes
shrinkage of the external elastic membrane at the lesion
site (12).
Examination of restenosis after experimental
angioplasty revealed that arterial remodelling in the
form of chronic constriction correlated more with
restenosis after angioplasty than neointimal-medial
growth (21). Intravascular ultrasound studies show that
negative remodelling accounts for 2/3 of lumen loss in
restenosis following angioplasty (22). 
Stenting, however, was found to cause greater
neointimal growth but prevented arterial remodelling.
Their overall benefit over angioplasty was attributed to
the larger initial gain in lumen size (23). 
Oxidative stress is increased post angioplasty and
may also be involved in constrictive remodelling by
enhancing the breakdown of nitric oxide, a vasodilator,
thereby contributing to endothelial dysfunction (24). 
TREATMENT OF IN-STENT RESTENOSIS
Prior to the relatively recent introduction of drug
eluting stents, brachytherapy was the only treatment
effective in significantly reducing in-stent restenosis.
The mechanisms that govern these treatments are
described below.
Brachytherapy
This non-pharmacological treatment delivers intra-
coronary sources of ß or γ radiation thereby inhibiting
cell proliferation in both media and adventitia, reducing
both neointimal accumulation and adventitial
myofibroblast accumulation. 
Intracoronary brachytherapy also prevents
constrictive remodelling thought to be a result of
reduction in the healing process and can even induce
positive remodelling resulting in luminal enlargement.
In the SCRIPPS trial, catheter-based brachytherapy was
shown to reduce restenosis rates and this was
maintained up to three years (25). 
However, there are serious limitations to this
treatment. One of these is edge restenosis whereby
stenosis occurs at the ends or outside the stents, which
could be a proliferative effect of low radiation doses on
damaged tissue. Late thrombosis can also occur
resulting in higher rates of late myocardial infarction. 
Other limitations include failure of healing of medial
dissections, acceleration of neointimal thickening at
some doses or after chronic therapy and delayed
reendothelialization. This type of non-specific treatment
is able to target multiple mechanisms of restenosis but
the non-specificity also limits this treatment by
inhibiting the healing process (13).
Drug Eluting Stents
The introduction of drug eluting stents has been seen
as another breakthrough in percutaneous coronary
intervention. This is because of the dramatic reduction
in restenosis rates not achieved by any previous
treatments. Clinical studies showed rates of 5% or lower
(26). 
Drug eluting stents achieve these rates by inhibiting
multiple biological processes that lead to restenosis.
The scaffolding of the stent prevents recoil while the
drugs delivered work on the surrounding tissue to
prevent neointimal hyperplasia. Also drug eluting stents
can deliver higher concentrations of a drug locally
without systemic effects (11).
Rapamycin (Sirolimus) 
Rapamycin modulates immune function and acts on
T-lymphocyte activation and cell proliferation. It enters
cells easily because of its lipophilic property and then
binds to an intracellular receptor called FKBP12. This
complex then increases cellular cyclin dependent kinase
inhibitor (CDKI) p27 and inhibits the action of
retinoblastoma protein (pRb), which regulates vascular
smooth muscle cell proliferation (11, 13). 
Inhibition of vascular smooth muscle cell
proliferation and migration occurs as a result of growth
arrest between G1 and S phases of the cell cycle.
Rapamycin also inhibits inflammation after injury by
inhibiting T-lymphocyte proliferation and activation.
The biological effects of rapamycin lead to overall
inhibition of neointimal formation thereby reducing
restenosis (11, 13).
Paclitaxel
Paclitaxel belongs to a group of drugs called taxanes
which are antiproliferatives used in cancer treatment. It
inhibits cell proliferation and migration by promoting
polymerisation of tubulin dimers and subsequently
stabilising microtubules into an assembled state (11).
Microtubule disassembly is required for transition
between G2 and M phase of the cell cycle. Therefore
cell proliferation (such as in smooth muscle cells) is
inhibited by this drug. It is also lipophilic and therefore
rapidly taken up by cells. However, by altering the
cytoskeletal structure, Paclitaxel exerts long-lasting
effects in vascular smooth muscle cells (13).
Clinical trials have shown the positive outcomes of
using this drug, such as the ELUTES and ASPECT
trials which revealed a dose-dependent reduction in
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The multiple actions of rapamycin and paclitaxel
suggest they are the ideal agents to inhibit multiple
processes leading to in-stent restenosis. However, one
of the main concerns about this non-specific feature of
both brachytherapy and drug eluting stents is the
reduction in the healing process, which leads to loss of
reendothelialization and possible late thrombosis (13).
DES vs. BMS
The reduction in the need for new revascularisation
procedures has been the main clinical benefit of drug
eluting stents (DES) over bare metal stents (BMS),
shown in a great number of randomized controlled trials
since 2002 (27). This finding resulted in their
widespread use with estimates of DES accounting for
more than 90% of stents used in the USA and
Switzerland (28). 
Initial concerns over increased stent thrombosis with
DES compared to BMS were followed by several
reports evaluating the safety of the drug eluting stents.
These reports showed no significant differences
between DES and BMS in the incidence of stent
thrombosis during the first year of follow-up (29).  
However, there has been a growing concern about the
long-term safety of DES. At the World Congress of
Cardiology in September 2006, the results of two
independent meta-analyses were presented, showing a
higher incidence of death and MI in the first generation
DES compared to BMS at the latest follow-up of four
years and this is thought to reflect the incidence of stent
thrombosis. This has led to a heated debate about the
widespread use of DES (28). 
A series of meta-analyses evaluated the risk of very
late stent thrombosis (>12 months) with the use of DES.
One of these comprised of 6675 patients from 14
clinical trials and found that the incidence of very late
stent thrombosis (>1 year post procedure) was low but
that there was an increased risk of late thrombosis with
DES (30). In another meta-analysis comprising nine
double-blind trials and assessing the safety of sirolimus
and paclitaxel-eluting coronary stents, stent thrombosis
was more common in both DES compared with BMS
after 1 year. However, there was no significant
difference in the cumulative rates of death or MI at four
years.   
Recently, several meta-analyses have been carried out
and some of these have found there to be no significant
differences between the use of BMS and DES in the
rates of death, MI or stent thrombosis.   
One recent meta-analysis of seven randomized trials
comparing DES and BMS in acute myocardial
infarction (AMI), involved a total of 2357 patients with
a follow up of 8-12 months. The results showed the
DES to reduce the need for revascularisation
significantly in patients with AMI with no difference in
the incidence of death or MI compared to BMS.
Furthermore the DES were not found to increase the
risk of stent thrombosis at 1-year follow-up. However,
there was no data available on the higher risk group of
patients and the follow-up was limited to 12 months
(32).  
Another recent meta-analysis of four randomized
trials, comprising 1748 patients, compared the use of
sirolimus-eluting stents (SES) with BMS, with follow-
up of four years. Three of these trials included patients
with higher risk and more complex lesions. The authors
concluded there were no significant differences
between the two stents in the rates of death, MI or stent
thrombosis (27).
The evidence remains inconclusive about the risk of
stent thrombosis in DES and an update of the current
evidence regarding the safety of DES is due to be
presented at the next World Congress of Cardiology in
September 2007. 
New Developments
Within the stent industry there has been ongoing
research aimed at developing a type of stent that will
overcome the limitations of both bare metal stents and
first generation drug eluting stents. Thus the goal is to
prevent in-stent restenosis while promoting healing and
reendothelialization of the vessel to prevent late
thrombosis. 
The most promising of these new types of stents is the
biodegradable stents. The idea behind these is that
having widened the lumen of the vessel, the stent
remains  in situ only for the time needed to prevent
elastic recoil and constrictive remodelling. Thereafter,
the stent is slowly absorbed and metabolised by the
vessel until it disappears allowing reendothelialization
to take place (33).  
Currently bioabsorbable magnesium stents are in
clinical trials. In a recent multicentre study, results
showed that the stents can achieve an immediate lumen
enlargement similar to conventional metallic stents and
can be safely degraded after four months. Ongoing
research in this domain includes modifications to
prolong the degradation period (34).  
Furthermore, biodegradable stents can also be
designed to deliver drugs and these biodegradable drug
eluting stents would be able to prevent in-stent
restenosis with the added advantage of preventing late
stent thrombosis (35). The stents may also be used as a
delivery vehicle for genes to exert a beneficial anti-
proliferative effect on the arterial wall cells. Examples
include genes for endothelial nitric oxide synthase and
vascular endothelial growth factor. Gene transfer is now
in phase I studies in humans (36).   110 McGill Journal of Medicine 2007
Drug eluting stents are also undergoing development
so that the next generation of DES overcomes the
limitations of the first generation such as late
thrombosis. Recently, one of these DES has been put
forward to the Food and Drug Administration for
market approval in the U.S. This is the Xience V
everolimus-eluting stent, which has a thin metal
platform and the new drug has been shown to reduce
tissue proliferation in coronary vessels. Furthermore,
results of the clinical trials (SPIRIT) demonstrated no
stent thrombosis at 3 years (37).  
Following on from this, a bioabsorbable everolimus-
eluting stent has been developed and is also undergoing
clinical trials (ABSORB). In a recent trial of 30 patients,
at 30 days the device was successful in 93.5% of all
cases. There was also 100% safety as no patients
experienced a major adverse coronary event or stent
thrombosis. At 180 days, 3.3% of patients had major
adverse coronary events and no stent thrombosis.
Unfortunately there was a restenosis rate of 11.5% and
this was due to shrinkage of the stent. Currently the
stent is undergoing further development to resolve this
issue (38).  
The other type of DES that is being developed is the
EPC-capturing stent where the stent is coated with an
antibody (CD34+) that attracts endothelial progenitor
cells (EPCs). The goal of this DES is to promote
endothelial growth so the artery can heal faster to
prevent in-stent restenosis. In a recent study testing this
new DES, results showed excellent procedural success
with 3.7% target vessel revascularization at 6 months
(38). 
With the advent of newer and better developed DES,
the problems of in-stent restenosis and late thrombosis
could be a thing of the past with better long-term
outcomes for patients treated with the next generation
of DES.  
CONCLUSION
Prior to drug eluting stents, brachytherapy was the
only treatment that proved effective in reducing
restenosis. However brachytherapy showed significant
side effects and therefore the search was still on for a
solution to the problem of in-stent restenosis. 
This came with the introduction of drug eluting stents,
which has revolutionized coronary stenting. They have
been hailed as 'miracle' stents due to their almost zero
in-stent restenosis rate. The safety concerns have been
mainly directed at the first generation of DES.
Therefore, current advancements in the field of DES
could increase the efficacy and safety of future DES. 
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